Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1972 1
1977 2
1979 1
1982 3
1983 1
1984 2
1985 4
1986 1
1987 1
1988 2
1989 4
1990 3
1991 4
1992 2
1993 6
1994 6
1995 10
1996 7
1997 6
1998 13
1999 9
2000 5
2001 10
2002 13
2003 19
2004 12
2005 27
2006 24
2007 26
2008 32
2009 37
2010 50
2011 43
2012 58
2013 79
2014 93
2015 113
2016 140
2017 101
2018 122
2019 142
2020 199
2021 228
2022 269
2023 290
2024 337
2025 10

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

2,280 results

Results by year

Filters applied: . Clear all
Page 1
Showing results for gupta reported d
Search for Gupta Repromed D instead (1 results)
Health benefits of resveratrol: Evidence from clinical studies.
Singh AP, Singh R, Verma SS, Rai V, Kaschula CH, Maiti P, Gupta SC. Singh AP, et al. Med Res Rev. 2019 Sep;39(5):1851-1891. doi: 10.1002/med.21565. Epub 2019 Feb 11. Med Res Rev. 2019. PMID: 30741437 Review.
The efficacy, safety, and pharmacokinetics of resveratrol have been documented in over 244 clinical trials, with an additional 27 clinical trials currently ongoing. Resveretrol is reported to potentially improve the therapeutic outcome in patients suffering from diabetes m …
The efficacy, safety, and pharmacokinetics of resveratrol have been documented in over 244 clinical trials, with an additional 27 clinical t …
Elective versus Therapeutic Neck Dissection in Node-Negative Oral Cancer.
D'Cruz AK, Vaish R, Kapre N, Dandekar M, Gupta S, Hawaldar R, Agarwal JP, Pantvaidya G, Chaukar D, Deshmukh A, Kane S, Arya S, Ghosh-Laskar S, Chaturvedi P, Pai P, Nair S, Nair D, Badwe R; Head and Neck Disease Management Group. D'Cruz AK, et al. N Engl J Med. 2015 Aug 6;373(6):521-9. doi: 10.1056/NEJMoa1506007. Epub 2015 May 31. N Engl J Med. 2015. PMID: 26027881 Free article. Clinical Trial.
As prespecified by the data and safety monitoring committee, this report summarizes results for the first 500 patients (245 in the elective-surgery group and 255 in the therapeutic-surgery group), with a median follow-up of 39 months. ...
As prespecified by the data and safety monitoring committee, this report summarizes results for the first 500 patients (245 in the el …
Chloracne.
Singh S, Manoj R, Gupta A. Singh S, et al. JAMA Dermatol. 2024 Jun 1;160(6):668-669. doi: 10.1001/jamadermatol.2024.0928. JAMA Dermatol. 2024. PMID: 38717755
This case report describes hyperpigmented, pruritic lesions on the patient's face and chest that worsened over the previous 3 weeks....
This case report describes hyperpigmented, pruritic lesions on the patient's face and chest that worsened over the previous 3 weeks.. …
A brief diet intervention can reduce symptoms of depression in young adults - A randomised controlled trial.
Francis HM, Stevenson RJ, Chambers JR, Gupta D, Newey B, Lim CK. Francis HM, et al. PLoS One. 2019 Oct 9;14(10):e0222768. doi: 10.1371/journal.pone.0222768. eCollection 2019. PLoS One. 2019. PMID: 31596866 Free PMC article. Clinical Trial.
There was good compliance with the diet intervention recommendations assessed using self-report and spectrophotometry. The Diet group had significantly lower self-reported depression symptoms than the Control Group on the CESD-R (p = 0.007, Cohen's d = 0.65) …
There was good compliance with the diet intervention recommendations assessed using self-report and spectrophotometry. The Diet group …
Pembrolizumab in Patients With Advanced Triple-Negative Breast Cancer: Phase Ib KEYNOTE-012 Study.
Nanda R, Chow LQ, Dees EC, Berger R, Gupta S, Geva R, Pusztai L, Pathiraja K, Aktan G, Cheng JD, Karantza V, Buisseret L. Nanda R, et al. J Clin Oncol. 2016 Jul 20;34(21):2460-7. doi: 10.1200/JCO.2015.64.8931. Epub 2016 May 2. J Clin Oncol. 2016. PMID: 27138582 Free PMC article. Clinical Trial.
METHODS: KEYNOTE-012 (ClinicalTrials.gov identifier: NCT01848834) was a multicenter, nonrandomized phase Ib trial of single-agent pembrolizumab given intravenously at 10 mg/kg every 2 weeks to patients with advanced PD-L1-positive (expression in stroma or 1% of tumor cells by imm …
METHODS: KEYNOTE-012 (ClinicalTrials.gov identifier: NCT01848834) was a multicenter, nonrandomized phase Ib trial of single-agent pembrolizu …
Vitamin D deficiency in India.
Aparna P, Muthathal S, Nongkynrih B, Gupta SK. Aparna P, et al. J Family Med Prim Care. 2018 Mar-Apr;7(2):324-330. doi: 10.4103/jfmpc.jfmpc_78_18. J Family Med Prim Care. 2018. PMID: 30090772 Free PMC article. Review.
Vitamin D is a fat-soluble vitamin playing a vital role in human physiology. Vitamin D deficiency is prevalent worldwide. ...With this review, we aim to summarize the existing literature on Vitamin D status in India and understand the enormity of the problem. …
Vitamin D is a fat-soluble vitamin playing a vital role in human physiology. Vitamin D deficiency is prevalent worldwide. ...W …
2023 White Paper on Recent Issues in Bioanalysis: ISR for ADA Assays, the Rise of dPCR vs qPCR, International Reference Standards for Vaccine Assays, Anti-AAV TAb Post-Dose Assessment, NanoString Validation, ELISpot as Gold Standard (Part 3 - Recommendations on Gene Therapy, Cell Therapy, Vaccines Immunogenicity & Technologies; Biotherapeutics Immunogenicity & Risk Assessment; ADA/NAb Assay/Reporting Harmonization).
Mora J, Palmer R, Wagner L, Wu B, Partridge M, Meena, Sonderegger I, Smeraglia J, Bivi N, Dakappagari N, Diebold S, Garofolo F, Grimaldi C, Kalina W, Kamerud J, Kar S, Marshall JC, Mayer C, Melton A, Merdek K, Nolan K, Picard S, Shao W, Seitzer J, Tanaka Y, Tounekti O, Vigil A, Walravens K, Xu J, Xu W, Xu Y, Yang L, Zhu L, Verthelyi D, Kubiak RJ, Coble K, Gupta S, Abhari MR, Richards S, Song Y, Ullmann M, Calderon B, Cludts I, Gunn GR, Gupta S, Ishii-Watabe A, Manangeeswaran M, Maxfield K, McCush F, O'Day C, Peng K, Poetzl J, Rasamoelisolo M, Saad OM, Scheibner K, Shubow S, Song S, Thacker S. Mora J, et al. Bioanalysis. 2024 Apr;16(7):77-119. doi: 10.4155/bio-2024-0024. Epub 2024 Feb 22. Bioanalysis. 2024. PMID: 38389403
Peripheral nervous system manifestations of MOG antibody associated disease.
Gupta P, Paul P, Redenbaugh V, Guo Y, Lucchinetti C, Abdulrahman Y, Datta A, Shah S, Klein CJ, Pittock SJ, Flanagan EP, Dubey D. Gupta P, et al. Ann Clin Transl Neurol. 2024 Apr;11(4):1046-1052. doi: 10.1002/acn3.52001. Epub 2024 Jan 17. Ann Clin Transl Neurol. 2024. PMID: 38234084 Free PMC article.
Recent studies have reported the involvement of peripheral nervous system (PNS) in association with MOG-IgG, including isolated neuropathies. ...
Recent studies have reported the involvement of peripheral nervous system (PNS) in association with MOG-IgG, including isolated neuro …
Health-related quality of life in patients with newly diagnosed advanced ovarian cancer treated with niraparib vs placebo: Results from the phase 3 randomized PRIMA/ENGOT-OV26/GOG-3012 trial.
Pothuri B, Han S, Chase DM, Heitz F, Burger RA, Gaba L, Van Le L, Guerra E, Bender D, Korach J, Cloven N, Churruca C, Follana P, DiSilvestro P, Baurain JF, Jardon K, Pisano C, Peen U, Mäenpää J, Gupta D, Bacqué E, Li Y, Compton N, Antonova J, Monk BJ, González-Martín A. Pothuri B, et al. Gynecol Oncol. 2024 May;184:168-177. doi: 10.1016/j.ygyno.2024.01.021. Epub 2024 Feb 6. Gynecol Oncol. 2024. PMID: 38325276 Free article. Clinical Trial.
OBJECTIVE: To assess patient-reported health-related quality of life (HRQoL) in patients with ovarian cancer (OC) who received niraparib as first-line maintenance therapy. ...HRQoL was assessed as a prespecified secondary end point using patient-reported responses t …
OBJECTIVE: To assess patient-reported health-related quality of life (HRQoL) in patients with ovarian cancer (OC) who received nirapa …
2,280 results